Baseline characteristics | All patients n = 46 | Responders n = 36 | Non-responders n = 10 | p value |
---|---|---|---|---|
Age (yrs) | 63 ± 10 | 64 ± 10 | 60 ± 8 | 0.183 |
Female | 5 | 5 | 0 | 0.570 |
GFR ml/min | 91 ± 33 | 88 ± 34 | 101 ± 27 | 0.184 |
BSA (m 2 ) | 2 ± 0.2 | 2 ± 0.3 | 2 ± 0.1 | 0.516 |
Hypertension | 42 | 32 | 10 | 0.562 |
Diabetes mellitus | 7 | 5 | 2 | 0.786 |
Previous documented MI | 42 | 32 | 10 | 0.562 |
NYHA functional class | 2.7 ± 0.8 | 2.6 ± 0.8 | 2.7 ± 1.0 | 0.634 |
CABG | 34 | 26 | 8 | 0.512 |
ONBEAT | 7 | 6 | 1 | 0.518 |
ONSTOP | 27 | 20 | 7 | 0.518 |
Nr. of distal anastomoses | 2.3 ± 1.6 | 2.2 ± 1.6 | 2.6 ± 1.6 | 0.422 |
LIMA | 27 | 22 | 5 | 0.195 |
PCI | 12 | 10 | 2 | - |
Beta-blocker | 40 | 31 | 9 | 1.000 |
ACE inhibitor | 33 | 27 | 6 | 0.351 |
Statin | 37 | 28 | 9 | 0.389 |
Duration between revascularisation and follow-up CMR (weeks) | 28 ± 4 | 28 ± 3 | 29 ± 8 | 0.704 |
LVEF (%) | 35 ± 8 | 36 ± 8 | 32 ± 7 | 0.041 |
LVEF 30% or less | 10 | 7 | 3 | 0.474 |
LV EDVI (ml/m 2 ) | 95 ± 35 | 90 ± 35 | 114 ± 30 | 0.035 |
LV ESVI (ml/m 2 ) | 62 ± 28 | 58 ± 28 | 77 ± 22 | 0.009 |
LV SI | 0.56 ± 0.1 | 0.55 ± 0.1 | 0.6 ± 0.1 | 0.068 |
WMSI | 1.9 ± 0.4 | 1.8 ± 0.4 | 2.2 ± 0.4 | 0.003 |
Total LGE score | 1.0 ± 0.6 | 0.9 ± 0.6 | 1.2 ± 0.7 | 0.170 |
LGE mass (g) | 31 ± 21 | 29 ± 21 | 36 ± 21 | 0.311 |